Author： Turpie Alexander GG
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.6, 2004-06, pp. : 1373-1384
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
By Sato K. Taniuchi Y. Kawasaki T. Hirayama F. Koshio H. Matsumoto Y.
European Journal of Pharmacology, Vol. 347, Iss. 2, 1998-04 ,pp. :
Access to resources
Recommend
By Sato K. Kawasaki T. Taniuchi Y. Hirayama F. Koshio H. Matsumoto Y.
European Journal of Pharmacology, Vol. 339, Iss. 2, 1997-11 ,pp. :
By Heran C. Morgan S. Kasiewski C. Bostwick J. Bentley R. Klein S. Chu V. Brown K. Colussi D. Czekaj M. Perrone M. Leadley R.
European Journal of Pharmacology, Vol. 389, Iss. 2, 2000-02 ,pp. :
Edoxaban: A New Oral Direct Factor Xa Inhibitor
By Camm A. John
Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. :
Rivaroxaban, the first oral, direct factor Xa inhibitor
Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. :